Abstract
Background: A rare type of cutaneous adverse drug reaction (CADR), lichenoid drug eruption (LDE), can be associated with ethambutol.
Case Report: A 60-year-old woman with spinal tuberculosis received multiple anti-TB medications and developed rashes after 3 months of the treatments. A skin biopsy from the posterior auricular area confirmed lichenoid dermatitis, and the Naranjo causality assessment indicated ethambutol as a probable cause of LDE in the patient. The rashes slowly improved after discontinuation of ethambutol. Unfortunately, the residual of brown hyperpigmentation on the body still persisted for over 16 months.
Conclusion: The medications were reduced to isoniazid 300 mg/day and rifampicin 450 mg /day as planned for another 3 months. This case report points out the essentials of early recognition of ethambutol LDE by health care professionals.
Keywords: Case report, ethambutol, lichenoid drug eruption, lichen planus, cutaneous adverse drug reaction (CADR), tuberculosis (TB), LDE.
Current Drug Safety
Title:Ethambutol Induced Lichenoid Drug Eruption: A Case Report
Volume: 16 Issue: 3
Author(s): Thitaree Yuyaem, Patcharaporn Sudchada*, Chutika Srisuttiyakorn, Jirapan Juntawong, Naruemon Khanngern, Natwara Watcharapokin and Pitchayakorn Chansangiam
Affiliation:
- Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok,Thailand
Keywords: Case report, ethambutol, lichenoid drug eruption, lichen planus, cutaneous adverse drug reaction (CADR), tuberculosis (TB), LDE.
Abstract:
Background: A rare type of cutaneous adverse drug reaction (CADR), lichenoid drug eruption (LDE), can be associated with ethambutol.
Case Report: A 60-year-old woman with spinal tuberculosis received multiple anti-TB medications and developed rashes after 3 months of the treatments. A skin biopsy from the posterior auricular area confirmed lichenoid dermatitis, and the Naranjo causality assessment indicated ethambutol as a probable cause of LDE in the patient. The rashes slowly improved after discontinuation of ethambutol. Unfortunately, the residual of brown hyperpigmentation on the body still persisted for over 16 months.
Conclusion: The medications were reduced to isoniazid 300 mg/day and rifampicin 450 mg /day as planned for another 3 months. This case report points out the essentials of early recognition of ethambutol LDE by health care professionals.
Export Options
About this article
Cite this article as:
Yuyaem Thitaree , Sudchada Patcharaporn *, Srisuttiyakorn Chutika , Juntawong Jirapan , Khanngern Naruemon , Watcharapokin Natwara and Chansangiam Pitchayakorn, Ethambutol Induced Lichenoid Drug Eruption: A Case Report, Current Drug Safety 2021; 16 (3) . https://dx.doi.org/10.2174/1574886315666201217095950
DOI https://dx.doi.org/10.2174/1574886315666201217095950 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Isoprostanes - Unique Products of Arachidonate Peroxidation: Their Role as Mediators of Oxidant Stress
Current Pharmaceutical Design Advances in the Treatment of Autoimmune Diseases; Cellular Activity, Type-1/Type-2 Cytokine Secretion Patterns and their Modulation by Therapeutic Peptides
Current Medicinal Chemistry COVID-19 and Inflammatory Markers
Current Vascular Pharmacology Pharma-metabolomics in Neonatology: is it a Dream or a Fact?
Current Pharmaceutical Design Systemic Involvement of IgG4-related Sclerosing Disease
Current Immunology Reviews (Discontinued) Insights into Peptide Mediated Antibiofilm Treatment in Chronic Wound: A Bench to Bedside Approach
Current Protein & Peptide Science Identification of HLA-A11-Restricted HIV-1-Specific Cytotoxic Tlymphocyte Epitopes in China
Current HIV Research The TLR9 Antagonist iCpG-ODN at Different Dosages Inhibits Cerebral Ischemia/Reperfusion Injury in Mice
CNS & Neurological Disorders - Drug Targets The Mouse Model of Chlamydia Genital Tract Infection: A Review of Infection, Disease, Immunity and Vaccine Development
Current Molecular Medicine The Biological Functions of NF-κB1 (p ) and its Potential as an Anti-Cancer Target
Current Cancer Drug Targets Soy Phytoestrogens and Breast Cancer Chemoprevention: Molecular Mechanisms
Current Nutrition & Food Science Oxidative/Nitrosative Stress and Immuno-inflammatory Pathways in Depression: Treatment Implications
Current Pharmaceutical Design Plant Antimicrobial Peptides: An Overview of SuperSAGE Transcriptional Profile and a Functional Review
Current Protein & Peptide Science Diagnosis and New Treatment Modalities for Glioblastoma: Do They Improve Patient Survival?
Current Molecular Medicine Targeting Upstream Kinases of STAT3 in Human Medulloblastoma Cells
Current Cancer Drug Targets Adverse Reactions to Iodinated Contrast Media Administered at the Time of Endoscopic Retrograde Cholangiopancreatography (ERCP)
Inflammation & Allergy - Drug Targets (Discontinued) Patent Ductus Arteriosus in Extreme Prematurity: Role of Echocar-diography and Other Imaging Techniques
Current Pediatric Reviews Association Study of 10 Candidate Genes with Sporadic Alzheimers Disease in a Spanish Population
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Long-Term Effectiveness and Safety Outcomes in HIV-1-Infected Patients After a Median Time of 6 Years on Nevirapine
Current HIV Research Combined Therapies for Lysosomal Storage Diseases
Current Molecular Medicine